Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
MALVERN, Pa., March 29, 2017 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, at 11:40 a.m. EDT at The Westin New York Grand Central in New York City.
For additional information on the conference, please visit:
http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx.
About PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio's lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact: Laura Bagby, 6 Degrees (312) 448-8098 [email protected]
